US FDA declines to approve expanded use of Dynavax’s hepatitis B vaccine

(Reuters) – The U.S. Food and Drug Administration has declined to approve the expanded use of Dynavax Technologies’ hepatitis B vaccine in patients undergoing hemodialysis, the company said on Tuesday.

(Reporting by Christy Santhosh and Pratik Jain in Bengaluru; Editing by Tasim Zahid and Shilpi Majumdar)